Vir Biotechnology Inc’s filing revealed that its Former Director GEORGE SCANGOS acquired Company’s shares for reported $0.11 million on Jun 11 ’25. In the deal valued at $5.41 per share,19,957 shares were bought.
Then, GEORGE SCANGOS bought 50,000 shares, generating $273,885 in total proceeds.
Before that, GEORGE SCANGOS bought 50,000 shares. Vir Biotechnology Inc shares valued at $270,590 were divested by the Former Director at a price of $5.41 per share.
JP Morgan downgraded its Vir Biotechnology Inc [VIR] rating to a Neutral from a an Overweight in a research note published on January 29, 2024; the price target was decreased to $9 from $23. A number of analysts have revised their coverage, including BofA Securities’s analysts, who decreased its forecast for the stock in early September from “a Buy” to “a Neutral”. JP Morgan also remained covering VIR and has increased its forecast on March 06, 2023 with a “an Overweight” recommendation from previously “Neutral” rating. Goldman revised its rating on February 21, 2023. It rated VIR as “a Buy” which previously was an “a Neutral”.
Price Performance Review of VIR
On Tuesday, Vir Biotechnology Inc [NASDAQ:VIR] saw its stock fall -2.67% to $5.10. Over the last five days, the stock has lost -5.90%. Vir Biotechnology Inc shares have fallen nearly -30.52% since the year began. Nevertheless, the stocks have fallen -50.77% over the past one year. While a 52-week high of $14.45 was reached on 01/08/25, a 52-week low of $4.32 was recorded on 05/15/25.
Levels Of Support And Resistance For VIR Stock
The 24-hour chart illustrates a support level at 5.01, which if violated will result in even more drops to 4.92. On the upside, there is a resistance level at 5.23. A further resistance level may holdings at 5.36.
